Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $7.7MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director | Aug 20 '26 | Sale | $4.54 | 114,700 | $520,738 | 2,465,298 | Aug 21 04:59 PM |
| Schwab Andrew J. | Director | Aug 19 '26 | Sale | $4.76 | 45,147 | $214,900 | 2,579,998 | Aug 21 04:59 PM |
| Schwab Andrew J. | Director | Aug 21 '26 | Sale | $4.50 | 32,018 | $144,081 | 2,433,280 | Aug 21 04:59 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.